Observes safety of filgotinib in Korean adults with arthritis or colitis
Watches filgotinib use in adults with rheumatoid arthritis or ulcerative colitis.
Key facts
- Who runs it
- Eisai Korea Inc.
- Where
- Ansan, Bucheon-si, Busan, Changwon, Cheonan, Cheongju-si, Chuncheon, Daegu, Daejeon, Goyang-si, Gwangju, Gwangmyeong, Incheon, Jeju City, Jeonju, Jinju, Sejong, Seongnam-si, Seoul, Suwon, Uijeongbu-si, Wŏnju, Yangsan, and Yŏngin, South KoreaSee the 59 sites
- Trial code
- Registry title
- A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants
- Status
- Recruiting
- People taking part
- 2,040 people, planned
- Started
- 27 Feb 2024
- Expected to end
- 30 Jul 2027
- Type of study
- Observational
- Record updated
- 6 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in Korea with moderately to severely active rheumatoid arthritis or ulcerative colitis who are taking Jyseleca tablet under its approved label.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Moderately to severely active rheumatoid arthritis or ulcerative colitis. Over age 65, high heart risk or cancer: only if other treatments did not work or were not tolerated.
- Earlier treatment
- Rheumatoid arthritis: inadequate response or intolerance to one or more DMARDs. Ulcerative colitis: inadequate response, lost response or intolerance to conventional therapy or biological agents. Jyseleca is not to be combined with biological DMARDs or other JAK inhibitors.
Main reasons for not taking part
- Allergy to Jyseleca or its ingredients
- Active infection or active tuberculosis
- Severe liver disorder or end-stage kidney disorder
- Pregnant, possibly pregnant or breastfeeding women
- Taking filgotinib in another clinical study
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Individuals who are being administered with Jyseleca tablet in accordance with the Korean approved label therapeutic indications
- Korean local label therapeutic indications of Jyseleca tablet. In the following participants, Jyseleca tablet should be used only if they do not respond appropriately or are intolerant to existing treatments
- Following:; Participants over 65 years of age; Participants with a high cardiovascular risk; Participants with malignancy
- Rheumatoid arthritis:; For treatment of moderately to severely active rheumatoid arthritis in adults who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs); Jyseleca tablet may be used as monotherapy or in combination with methotrexate (MTX); Jyseleca tablet should not be used in combination with biological DMARDs (bDMARDs) or other Janus kinase (JAK) inhibitors
- Ulcerative colitis:; For treatment of moderately to severely active ulcerative colitis in adults who have an inadequate response with, lost response to, or were intolerant to either conventional therapy (corticosteroids, immunosuppressants, etc.) or biological agents
- The investigator should refer to local label and contraindications in Korea regarding the inclusion criteria
Who cannot take part
- Individuals who fall under contraindications to the administration of Jyseleca tablet in accordance with the local label by the medical judgment of the investigator; Contraindication for Jyseleca tablet in accordance with the Korean label:; Participants with hypersensitivity to the active ingredient or other ingredients of the Jyseleca tablet; Participants with active infections, including serious (example, sepsis) or local infections; Participants with active tuberculosis; Participants with severe hepatic disorder; Participants with end-stage renal disorder; Participants with absolute neutrophil count (ANC) <1*10\^9 cells/liters (L); Participants with absolute lymphocyte count (ALC) <0.5*10\^9 cells/L; Participants with hemoglobin level <8 grams per deciliter (g/dL); Pregnant or potentially pregnant women, lactating women; Jyseleca tablet should not be administered to participants with genetic problems such as galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption as it contains lactose
- Individuals who are administered Filgotinib in a clinical study other than this post marketing surveillance
- Individuals who are considered incompatible with participate in this surveillance by the medical judgment of the investigator; The investigator should refer to local label and contraindications in Korea regarding the exclusion criteria
Where in South Korea
- Korea University Ansan HospitalAnsan, South KoreaContact: Serena SoYoun KwonTaking people
- The Catholic University of Korea, Bucheon St. Mary's HospitalBucheon-si, South KoreaContact: Serena SoYoun KwonTaking people
- Dong-A University HospitalBusan, South KoreaContact: Serena SoYoun KwonTaking people
- Haeundae Bumin HospitalBusan, South KoreaContact: Serena SoYoun KwonTaking people
- Inje University Haeundae Paik HospitalBusan, South KoreaContact: Serena SoYoun KwonTaking people
- Inje university Pusan Paik hospitalBusan, South KoreaContact: Serena SoYoun KwonTaking people
- Kosin University Gospel HospitalBusan, South KoreaContact: Serena SoYoun KwonTaking people
- Changwon Gyeongsang National University HospitalChangwon, South KoreaContact: Serena SoYoun KwonTaking people
- Changwon Fatima HospitalChangwon, South KoreaContact: Serena SoYoun KwonNo longer taking part
- Soonchunhyang University Cheonan HospitalCheonan, South KoreaContact: Serena SoYoun KwonTaking people
- Chungbuk National University HospitalCheongju-si, South KoreaContact: Serena SoYoun KwonTaking people
- Kangwon National University HospitalChuncheon, South KoreaContact: Serena SoYoun KwonTaking people
- Daegu Fatima HospitalDaegu, South KoreaContact: Serena SoYoun KwonTaking people
- Daegu Koo HospitalDaegu, South KoreaContact: Serena SoYoun KwonTaking people
- Deagu Catholic University Medical CenterDaegu, South KoreaContact: Serena SoYoun KwonTaking people
- Keimyung University Dongsan HospitalDaegu, South KoreaContact: Serena SoYoun KwonTaking people
- Kyungpook National University Chilgok HospitalDaegu, South KoreaContact: Serena SoYoun KwonTaking people
- Kyungpook National University HospitalDaegu, South KoreaContact: Serena SoYoun KwonTaking people
- Yeungnam University Medical CenterDaegu, South KoreaContact: Serena SoYoun KwonTaking people
- Catholic University of Korea Daejeon St. Mary's HospitalDaejeon, South KoreaContact: Serena SoYoun KwonTaking people
- Chungnam National University HospitalDaejeon, South KoreaContact: Serena SoYoun KwonTaking people
- Eulji University Hospital, DaejeonDaejeon, South KoreaContact: Serena SoYoun KwonTaking people
- Konyang University HospitalDaejeon, South KoreaContact: Serena SoYoun KwonTaking people
- Inje University Ilsan Paik HospitalGoyang-si, South KoreaContact: Serena SoYoun KwonTaking people
- Chosun University HospitalGwangju, South KoreaContact: Serena SoYoun KwonTaking people
- Jeonnam National University HospitalGwangju, South KoreaContact: Serena SoYoun KwonTaking people
- Chung-Ang University Gwangmyeong HospitalGwangmyeong, South KoreaContact: Serena SoYoun KwonTaking people
- Catholic Kwandong University International St.Mary's HospitalIncheon, South KoreaContact: Serena SoYoun KwonTaking people
- Gachon University Gil Medical CenterIncheon, South KoreaContact: Serena SoYoun KwonTaking people
- Jeju National University HospitalJeju City, South KoreaContact: Serena SoYoun KwonTaking people
- jeonbuk National University HospitalJeonju, South KoreaContact: Serena SoYoun KwonTaking people
- Gyeongsang National University HospitalJinju, South KoreaContact: Serena SoYoun KwonTaking people
- Sejong Chungnam National University HospitalSejong, South KoreaContact: Serena SoYoun KwonTaking people
- CHA Bundang Medical CenterSeongnam-si, South KoreaContact: Serena SoYoun KwonTaking people
- Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Serena SoYoun KwonTaking people
- Asan Medical CenterSeoul, South KoreaContact: Serena SoYoun KwonTaking people
- Catholic University of Korea Seoul ST. Mary's HospitalSeoul, South KoreaContact: Serena SoYoun KwonTaking people
- Catholic University of Korea Yeouido St. Mary's HospitalSeoul, South KoreaContact: Serena SoYoun KwonTaking people
- Chung ang University HospitalSeoul, South KoreaContact: Serena SoYoun KwonTaking people
- Gangnam Severance HospitalSeoul, South KoreaContact: Serena SoYoun KwonTaking people
- Hanyang University Medical CenterSeoul, South KoreaContact: Serena SoYoun KwonTaking people
- HoYounKim's ClinicSeoul, South KoreaContact: Serena SoYoun KwonTaking people
- Kangbuk Samsung HospitalSeoul, South KoreaContact: Serena SoYoun KwonTaking people
- Konkuk University Medical CenterSeoul, South KoreaContact: Serena SoYoun KwonTaking people
- Kyung Hee University HospitalSeoul, South KoreaContact: Serena SoYoun KwonTaking people
- Kyung Hee University Hospital at GangdongSeoul, South KoreaContact: Serena SoYoun KwonTaking people
- Samsung Medical CenterSeoul, South KoreaContact: Serena SoYoun KwonTaking people
- Seoul National University HospitalSeoul, South KoreaContact: Serena SoYoun KwonTaking people
- Severance hospitalSeoul, South KoreaContact: Serena SoYoun KwonTaking people
- SNU Boramae Medical CenterSeoul, South KoreaContact: Serena SoYoun KwonTaking people
- SoonChunHyang University Hospital SeoulSeoul, South KoreaContact: Serena SoYoun KwonTaking people
- Korea University Guro HospitalSeoul, South KoreaContact: Serena SoYoun KwonNo longer taking part
- Ajou University Medical CenterSuwon, South KoreaContact: Serena SoYoun KwonTaking people
- The Catholic University of Korea St. Vincent's HospitalSuwon, South KoreaContact: Serena SoYoun KwonTaking people
- Nowon Eulji HospitalUijeongbu-si, South KoreaContact: Serena SoYoun KwonTaking people
- Uijeongbu Eulji Medical CenterUijeongbu-si, South KoreaContact: Serena SoYoun KwonTaking people
- Wonju Severance Christian HospitalWŏnju, South KoreaContact: Serena SoYoun KwonTaking people
- Pusan National University Yangsan HospitalYangsan, South KoreaContact: Serena SoYoun KwonTaking people
- Yongin Severance HospitalYŏngin, South KoreaContact: Serena SoYoun KwonTaking people
About the trial
What the trial wants to find out
The purpose of this study is to collect and evaluate the following information in relation to the safety and the efficacy of Jyseleca tablet (Filgotinib Maleate) 100 milligram (mg) and 200 mg in this post marketing setting: (1) Serious adverse events and adverse drug reactions (2) Unexpected adverse events and adverse drug reactions not reflected in precautions for use (3) Known adverse drug reactions (4) Non-serious adverse events and adverse drug reactions (5) Other safety and effectiveness related information will be evaluated in accordance with the permitted articles under the actual conditions of use in Korea.
The group in the trial
- All Participants
Korean participants who are prescribed with Jyseleca (Filgotinib Maleate) tablet 100 mg and 200 mg per approved prescribing information of Filgotinib Maleate in the post marketing setting will be enrolled and observed for up to 24 weeks or until discontinuation of treatment due to AEs or any other reason, whichever occurs first.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Post Marketing Surveillance of Jyseleca Tab. (Filgotinib Maleate) in Korean Subjects
- Plain-language title
- Observes safety of filgotinib in Korean adults with arthritis or colitisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 6 July 2026